Gampa Siri Chandana, Garimella Sireesha V
Department of Biotechnology, School of Science, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, 530045, India.
Curr Mol Med. 2025;25(5):567-588. doi: 10.2174/0115665240310780240805114133.
Breast Cancer (BC) is one of the most frequently occuring diseases in women, accounting for 90% of cancer-related deaths in women. Tumor cells can invade nearby tissues and spread to distant organs by metastasis. The epithelialmesenchymal transition or EMT, which involves a number of transcription factors and signaling pathways, is a mechanism by which cells of the epithelium change into mesenchymal type capable of motility, invasion, and metastasis. EMT has grown to be a more intriguing target for developing cutting-edge treatment approaches since it is involved in diverse malignant transformation-related activities. Besides preventing tumor cell invasion and spread and the development of metastatic lesions, anti-EMT treatment methods also lessen cancer stemness and improve the efficacy of more traditional chemotherapeutics. EMT is, therefore, a desirable target in oncology. This review gives an overview of EMT, various markers of EMT, and different inhibitors used in therapies targeting EMT in BC.
乳腺癌(BC)是女性中最常见的疾病之一,占女性癌症相关死亡人数的90%。肿瘤细胞可侵袭附近组织并通过转移扩散至远处器官。上皮-间质转化(EMT)涉及多种转录因子和信号通路,是上皮细胞转变为具有运动、侵袭和转移能力的间充质类型细胞的一种机制。由于EMT参与多种与恶性转化相关的活动,它已成为开发前沿治疗方法更具吸引力的靶点。除了预防肿瘤细胞侵袭、扩散和转移病灶的形成外,抗EMT治疗方法还可降低癌症干性并提高更传统化疗药物的疗效。因此,EMT是肿瘤学中一个理想的靶点。本综述概述了EMT、EMT的各种标志物以及用于BC中靶向EMT治疗的不同抑制剂。